SEARCH:   Advanced

Blood, 1 July 2004, Vol. 104, No. 1, pp. 40-42. Prepublished online as a Blood First Edition Paper on March 9, 2004; DOI 10.1182/blood-2003-10-3400. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-10-3400v1 104/1/40    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ma, C. X. Articles by Gertz, M. A. Search for Related Content PubMed PubMed Citation Articles by Ma, C. X. Articles by Gertz, M. A. Related Collections Neoplasia Brief Reports Clinical Trials and Observations Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Brief report Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma Cynthia X. Ma, Martha Q. Lacy, John F. Rompala, Angela Dispenzieri, S. Vincent Rajkumar, Philip R. Greipp, Rafael Fonseca, Robert A. Kyle, and Morie A. Gertz From the Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN. Adult-acquired Fanconi syndrome (FS) is a rare complication of monoclonal gammopathy. We retrospectively reviewed 32 patients diagnosed with adult-acquired FS between April 1968 and June 2002 at Mayo Clinic (Rochester, MN). At diagnosis, most patients had monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM), with a median creatinine level of 176.8 µM (2.0 mg/dL; range, 79.56-327.08 µM [0.9-3.7 mg/dL]) and evidence of osteomalacia. During the average 65 months (range, 2-238 months) of follow-up, 5 patients developed end-stage renal disease (ESRD) and only 1 of 14 patients with MGUS transformed to multiple myeloma (MM). Also, 14 deaths occurred, with only 1 from ESRD but 4 from alkylator-related leukemia or myelodysplastic syndrome. Chemotherapy offered little benefit on renal functions of MGUS or SMM patients. In conclusion, FS associated with monoclonal gammopathy does not appear to confer an additional risk of subsequent evolution to MM. ESRD occurs late in the disease process. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Best therapy for primary amyloidosis, a not-yet-solved question Arnaud Jaccard, Philippe Moreau, Veronique Leblond, and Jean-Paul Fermand Blood 2004 104: 2990-2991. [Full Text] [PDF] This article has been cited by other articles: S C CHUA, S R O'CONNOR, W L WONG, and R H GANATRA Solitary plasmacytoma of bone with oncogenic osteomalacia: recurrence of tumour confirmed by PET/CT. A case report with a review of the radiological literature Br. J. Radiol., April 1, 2008; 81(964): e110 - e114. [Abstract] [Full Text] [PDF] R. Khoriaty, Z. K. Otrock, W. A. Medawar, R. B. Khauli, and A. Bazarbachi A case of successful double sequential bone marrow and kidney transplantations in a patient with multiple myeloma Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3585 - 3588. [Full Text] [PDF] M. A. Gertz Managing Myeloma Kidney Ann Intern Med, December 6, 2005; 143(11): 835 - 837. [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020